永久性下腔静脉滤器预期效用更高且预测成本更低
本研究通过马尔可夫决策树模型比较可回收与永久性下腔静脉滤器的效用和成本。基础分析显示永久性滤器QALY更高(5.41 vs 5.33)且成本更低(2070 vs 4650美元)。敏感性分析表明无论回收率如何,可回收滤器策略均不优于永久性滤器。
要点
- 永久性滤器预期效用更高且成本更低。
- 可回收滤器策略在任何回收率下均不占优。
- 除非长期并发症率显著改善,否则应弃用可回收滤器。
核心结论
- 永久性下腔静脉滤器的预测效用高于可回收滤器,且预测成本更低,无论滤器回收率如何。
- 除非可回收滤器的长期并发症率能显著改善,否则应放弃使用可回收滤器,转而使用现有永久性滤器。
研究设计与样本
- 构建马尔可夫决策树模型,比较可回收与永久性下腔静脉滤器的效用和成本。
- 效果概率来自已发表数据综述,效用值来自Tufts医学中心成本-效用分析注册库,成本以Medicare报销费率作为代理。
- 对多种参数进行敏感性分析,主要确定可回收滤器优于永久性滤器的回收率阈值。
主要发现
- 基础案例分析显示永久性滤器预测效用更高(5.41 QALY vs 5.33 QALY)且成本更低(2070美元 vs 4650美元)。
- 10000次迭代的蒙特卡洛模拟证实永久性滤器的预期效用(5.4 ± 3.0 QALY vs 5.3 ± 3.0 QALY;P = .0002)和成本(1900 ± 7400美元 vs 4800 ± 9900美元;P < .0001)具有统计学优势。
- 对滤器回收率的敏感性分析显示,可回收滤器策略在效用或成本方面从未更优。
- 无论预期患者年死亡率如何,永久性滤器在效果和成本上的优势持续存在。
- 对滤器移除率和患者年死亡率的双向敏感性分析证实,在所有水平上永久性滤器放置均占优。
临床怎么用
- 在临床决策中,永久性下腔静脉滤器可能比可回收滤器更具成本效益。
- 可回收滤器的使用需谨慎评估,除非其长期并发症率能显著改善。
局限性
- 研究基于已发表数据的模型预测,可能受数据质量和假设影响。
- 成本以Medicare报销费率为代理,可能不完全反映实际临床成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Retrievable inferior vena cava (IVC) filters were first approved for use in the United States in 2003 to address the long-term complications of migration, thrombosis, fracture, and perforation observed with permanent IVC filter implantation. Although Food and Drug Administration approval of retrievable IVC filters includes permanent implantation, the incidence of complications from long-term implantation appears to be greater than that reported with existing permanent IVC filters. Also, only a small fraction of such retrievable IVC filters are ever retrieved. The purpose of the present study was to determine the threshold retrieval rate at which the use of retrievable IVC filters could be justified. METHODS: A Markov decision tree was constructed comparing retrievable and permanent IVC filters regarding their effectiveness and cost. A review of the reported data provided outcome probabilities, and the Tufts Medical Center Cost-Effectiveness Analysis Registry was the source of the utility values for the various potential outcomes. Medicare reimbursement rates served as a proxy for costs. A sensitivity analysis was performed for various parameters, primarily to determine the retrieval rate threshold at which the use of retrievable IVC filters would outperform the use of permanent IVC filters. RESULTS: Base case analysis demonstrated a greater predicted effectiveness for permanent compared with retrievable IVC filter implantation (5.41 quality-adjusted life-years [QALY] vs 5.33 QALY) at a lower cost ($2070 vs $4650). Monte Carlo simulation at 10,000 iterations confirmed the expected utility (5.4 ± 3.0 QALY vs 5.3 ± 3.0 QALY; P = .0002) and cost ($1900 ± $7400 vs $4800 ± 9900; P < .0001) to be statistically superior for permanent IVC filters. A sensitivity analysis for the filter retrieval rate demonstrated that the strategy of using a retrievable IVC filter was never preferable for utility or cost. The superiority of permanent IVC filter placement for effectiveness and cost persisted, regardless of anticipated patient-predicted annual mortality. A two-way sensitivity analysis for both IVC filter removal rate and annual patient mortality confirmed the superiority of permanent IVC filter placement at all levels. CONCLUSIONS: The predicted effectiveness of permanent IVC filters was greater and the predicted cost lower than those for retrievable IVC filters, regardless of the IVC filter retrieval rate. This interpretation of existing reported data using Markov decision analysis modeling supports the argument that unless the long-term complication rate of retrievable IVC filters can be significantly improved, their use should be abandoned in favor of currently available permanent IVC filters.
引用
- Brothers TE, Todoran TM. Permanent inferior vena cava filters offer greater expected patient utility at lower predicted cost. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32335332. doi:10.1016/j.jvsv.2020.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。